¹⁸F-FDG-PET/CT in malignant mesothelioma

Biomed Pharmacother. 2013 Jul;67(6):539-42. doi: 10.1016/j.biopha.2013.01.008. Epub 2013 Feb 18.

Abstract

It is well known the useful role of ¹⁸F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of ¹⁸F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of ¹⁸F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.

Keywords: (18)F-FDG-PET/CT; Malignant mesothelioma; Prognosis; Radiation therapy planning; Treatment response.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18 / administration & dosage*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / pathology
  • Mesothelioma / diagnostic imaging*
  • Mesothelioma / pathology
  • Mesothelioma, Malignant
  • Positron-Emission Tomography / methods
  • Prognosis
  • Radiopharmaceuticals / administration & dosage*
  • Tomography, X-Ray Computed / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18